Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Cantor initiatiate Overweight target 9$

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Nov 17, 2022 9:36am

113 Views

Post# 35106298

RE:RE:RE:RE:Cantor initiatiate Overweight target 9$

Just curious, does she have large amounts of cash coming in for cancer just heavily discounted atm?

SPCEO1 wrote: She has the following 2030 sales estimates:

Trogarzo - $97 million
Egrifta - $145 million
NASH - $371 million
Cancer - $120 million

As I said in my previous post, the analyst's cancer number will likely come up considerably once/if THTX announces something positive there and a share offering lead by Cantor will come shortly thereafter. So, most of the difference between her $9 price target and the other analysts price targets is NASH and a small amount of cancer.

woodman1 wrote: Where would she get $9 US from? I hope it happens, but why don't other analysts see this?